Science

From medicinal plant knowledge to standardized pharmaceutical development.

Curaem's development approach is based on reverse pharmacology: beginning with medicinal plant knowledge, then applying modern validation including plant authentication, phytochemical analysis, marker-component selection, biological assays, hepatoprotective models, and clinical development planning.

Development pathway

A staged pathway from plant to candidate.

STEP 01
Botanical sourcing
STEP 02
Authentication
STEP 03
Phytochemical characterization
STEP 04
Marker-component selection
STEP 05
Standardized PHF preparation
STEP 06
In-vitro & in-vivo validation
STEP 07
Preclinical data package
STEP 08
Clinical-readiness planning
Validation framework

Four pillars of validation.

Botanical standardization

Plant authentication, phytochemical characterization, heavy metal and sterility screening.

Biological validation

Anti-HBV, antioxidant, cytotoxicity, and biomarker assays.

Hepatoprotective research

Preclinical evaluation across liver injury models including fibrosis, cirrhosis, and NAFLD.

Development readiness

Data packaging, clinical protocol planning, regulatory strategy, and manufacturing readiness.

Standardization matters

Rigor at every step — from cultivation to formulation.

Botanical-derived pharmaceutical development requires rigorous control of raw materials, marker components, cultivation conditions, and manufacturing consistency. Curaem's strategy is built on controlled cultivation and quality-standardized production planning.

Under NDA

Qualified scientific and strategic partners may request the detailed scientific package under NDA.

· Scientific data package
· Cultivation & manufacturing plan
· Regulatory strategy

Curaem's product candidates are investigational and have not been approved by any regulatory authority. This page is intended for scientific and partnership information only and does not provide medical advice.

Restricted access

Request the detailed scientific data package.

Qualified scientific and strategic partners may request the extended data package under NDA.